Please try another search
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Willy Jules Simon | 72 | 2015 | Senior Independent Non-Executive Director |
Gary S. Jacob | 76 | 2021 | CEO & Executive Director |
Bernard F. Denoyer | 75 | 2021 | Independent Non-Executive Director |
John Patrick Brancaccio | 74 | 2020 | Independent Non-Executive Director |
Gabriele Marco Antonio Cerrone | 51 | 2021 | Non-Executive Chairman |
Jay S. Pepose | 67 | 2023 | Member of Scientific Advisory Board |
Pedram Hamrah | - | - | Member of Scientific Advisory Board |
Mark Milner | - | 2024 | Member of Scientific Advisory Board |
Victor Perez | - | 2024 | Member of Scientific Advisory Board |
Anat Galor | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review